Phase 3 research of the Clarity AD study with BAN2401 was reported on 27 September 2022, by Biogen and Eisai [143], as top positive results in all primary and secondary experiments, whereby two-thirds of the treated group became PET-amyloid negative at 18 months, and PET-tau revealed a significant reduction in tangle accumulation in the medial temporal lobe and trended downward in other brain regions. Here, MAPT is linked to Alzheimer disease.